Skip navigation
Agenda

The World’s Largest and Highest Acclaimed Event for CFOs, Controllers and Finance Executives within the Life Sciences Sector

March 20-22, 2017
  • Philadelphia, PA

Agenda

Want more agenda details? Download the brochure.

DAY ONE MONDAY MARCH 20, 2017

12:30

Congress Registration

1:30 ATTENDEES CHOOSE BETWEEN 3 SUMMITS (I-III)

I PHARMA/BIOTECH GROUP ROUNDTABLE (PART I)

Participate in a hot topic exchange and industry-only roundtable, as accounting leaders from pharmaceutical and biotech companies delve into pressing matters, emerging accounting guidance issues, shared challenges and areas of disparity in practice.

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

II PHARMA ACCOUNTING PRACTICUM — A NEXT LEVEL BOOT CAMP FOR CORPORATE PREPARERS

Rev up your understanding of industryspecific nuances and reinforce your control of technical accounting issues with high impact to pharmaceutical and biotech companies. This long-standing boot camp takes education to the next level as attendees are surveyed in advance and live during the event to illustrate disparities in practice and to hone in on top learning objectives.

Mike Lombardo
Partner
Deloitte

Brian Jobe
Partner
Deloitte

Bruce Rucks
Partner
Deloitte

III GROWTH PATH — CHALLENGES AND OPPORTUNITIES FOR ACHIEVING ACCELERATED GROWTH

Discover how leading life science companies achieve and manage accelerated growth, and learn the key considerations and strategic ‘watch-outs’ for various maturity stages in the business lifecycle. Hear challenges and opportunities to guide your business and to map the path towards continued accelerating growth.

Winna Brown
Partner
Ernst & Young LLP

Lily Yang
Vice President of Finance and Accounting
Medivation

Anthony Sgammato
Partner
Ernst & Young LLP

Chip Baird
Chief Financial Officer
Amicus Therapeutics

Suketu “Suky” Upadhyay
Senior Vice President of Global Finance Operations
Bristol-Myers Squibb

3:00

Networking and Refreshment Break

3:30 ATTENDEES CHOOSE BETWEEN 3 SUMMITS (IV-VI)

IV PHARMA/BIOTECH GROUP ROUNDTABLE (PART II)

Continue the conversation with your industry peers, as key topics are discussed. This industry-only roundtable solicits top learning objectives from registered participants in advance, as the discussions are ultimately guided by these top-of-mind matters.

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

V GTN ESTIMATES AND ACCRUALS — MASTER CLASS

The materiality around GTN has magnified in recent years. For companies at all stages of commercial revenue and at various junctures in the life sciences product lifecycle, it is critical that the focus sharpen around GTN process, estimates and controls. This session parlays substantial GTN expertise into a Master Class for life science companies.

Mike Makovec
Audit Senior Manager
Deloitte & Touche LLP

Brad Schulte
Senior Manager
Deloitte & Touche LLP

Walt Worsham
Senior Manager
Deloitte & Touche LLP

Larry Breen
Director of Financial Planning and Analysis/Revenue Analytics
Sunovion

David Levi
Executive Director, Global Business Controls, Corporate Controller’s Office
Bristol-Myers Squibb

Jeffrey R. Miller
Director, Revenue Accounting and Contract Administration
Impax Labs

VI WOMEN’S LEADERSHIP SUMMIT Spotlights power players in the Finance function and shares stories on career paths, mentorship and leadership

An all-new, important Summit showcasing women in leadership within the finance and life sciences community. Hear compelling stories of personal career success, reflect on professional development paths, discover flashpoint moments, and ways to inspire and elevate the finance team. Attendees discover meaningful mentorships and insights into optimal job placement and professional pathways.

MODERATOR:

Karen Young
U.S. Pharmaceutical and Life Sciences Assurance Leader
PwC

PANELISTS:

Joyce LaViscount
Chief Financial Officer
Helius Medical

Kristine Ball
Former Chief Financial Officer
Relypsa

Sharon Greenlees
Vice President of Investor Relations
AbbVie

Ann Powell Judge
Chief Human Resources Officer
Bristol-Myers Squibb

Maria Teresa “Tessa” Hilado
Chief Financial Officer
Allergan (Invited)

5:00

Close of Day One

JOIN US FOR THE OPENING NIGHT WELCOME RECEPTION immediately following the final session on day one HOSTED BY: Ernst & YoungSiegfried Group

DAY TWO TUESDAY, MARCH 21, 2017

6:00

“Rocky Run”   Hosted by: PwC

Join PwC and industry colleagues in a morning “Rocky Run”. Participants depart the hotel at 6am and run just under 3 miles to the Philadelphia Art Museum, ascending the famous Rocky Steps and taking a photo with Rocky’s statue. Do not miss this traditional Philadelphia right of passage! Return transportation provided.

7:00

Breakfast and Registration

8:00

CBI Welcome

8:20

Co-Chairs’ Welcome and Opening Remarks

Cathy Engelbert
CEO
Deloitte LLP

Chris Cooper
Partner, National Audit Life Sciences and Health Care Leader
Deloitte & Touche LLP

9:00

KEYNOTE PANEL Product Pricing, Payer Pressure and Patient Access —
Transcending the Higher Bar in Today’s Value-Based Life Science Landscape

MODERATOR:

Karen Young
U.S. Pharmaceutical and Life Sciences Assurance Leader
PwC

PANELISTS:

Ira Klein
Senior Director of Healthcare Quality Strategy, Strategic Customer Group
Janssen Pharmaceuticals;
former National Medical Director for Clinical Thought Leadership
in the Office of the Chief Medical Officer, Aetna

Steve Miller
Chief Medical Officer
Express Scripts

Michelle Drozd
Deputy Vice President of Policy and Research
Pharmaceutical Research and Manufacturers of America (PhRMA)

Rebecca Shanahan
Chief Executive Officer
Avella Specialty Pharmacy

Matt Eyles
Executive Vice President, Policy & Regulatory Affairs
America’s Health Insurance Plans (AHIP)

10:00

Networking and Refreshment Break

10:30

LUMINARY SEGMENT Progressive Pharma —
Building Digital into the DNA of the Industry

This highly-acclaimed Luminary Segment showcases industry changemakers and illustrates innovation moonshots in the areas of R&D, technology, health outcomes and commercial finance. Discover how pharmaceutical companies are disrupting the course of business, reshaping the state of play, and truly elevating the patient experience.

MODERATOR:

Tim Gordon
Global FAAS Life Sciences Leader
Ernst & Young LLP

I. Transforming Clinical Research and Fueling Outcomes-driven, Patient-centric Drug Discovery and Development

LUMINARY:

Greg Simon
Director
Biden Cancer Initiative at Biden Foundation

II. Revolutionizing the Patient Journey and Catalyzing Commercial Innovation with Technology

LUMINARY:

Iya Khalil
Co-Founder and Chief Commercial Officer
GNS Healthcare

III. Optimizing Business Activities and Finance Transformation to Hit New Heights in Efficiency

LUMINARY:

Carolee Clarke-Reid
Director, Global Tax Operation
Johnson & Johnson

12:30

Networking Luncheon

REGULATORY INSIGHTS

MODERATOR:

Christine Davine
Deputy Managing Partner
Deloitte & Touche LLP

1:30

SEC KEYNOTE ADDRESS Impact of New Administration on SEC Priorities and Agenda

Wesley Bricker
Chief Accountant
U.S. Securities & Exchange Commission

2:10

SEC Hot Topics in the Life Sciences Industry —
Comment Letter Review and Key Industry Matters

James Rosenberg
Senior Assistant Chief Accountant in the Office of Health Care and Insurance
U.S. Securities & Exchange Commission

2:50

FASB ADDRESS The Future of Global Standard Setting and Initiatives to Make Standards More Comparable

Russell Golden
Chairman
FASB

3:30

MARKET MATTERS Walk Down Wall Street and View the Most Impactful Deals and Breakthroughs Impacting the Life Science Sector

MODERATOR:

Colin Wittmer
New York Metro Deals & Transaction Services Leader
PwC

PANELISTS:

Kennen MacKay, PhD
Vice President, Biotechnology Research Analyst
Credit Suisse

Gerardo Ubaghs
Vice President (Life Sciences), Global Healthcare Investment Banking
Bank of America Merrill Lynch

4:10

Networking and Refreshment Break

4:40 ATTENDEES CHOOSE FROM FOUR WORKSHOPS (A,B,D,E)

WORKSHOP A Accounting Considerations for Licensing Arrangements

Dennis Howell
Partner
Deloitte & Touche LLP

Robert Owens
Assistant Controller
Bristol-Myers Squibb

WORKSHOP B Applying the New Lease Standard

Shanti Gupta
Senior Manager
Ernst & Young LLP

Kevin MacKay
Assistant Corporate Controller
Pfizer Inc

Robert (Rob) Auslander, CPA, CGMA, MBA
Vice President, Technical Accounting and Policies
Valeant Pharmaceuticals International

Joe Fitzgerald
Executive Director
Ernst & Young LLP

WORKSHOP D Optimizing Controls and Compliance

Jim Quinlan
Partner
CFGI

Angela Celia
Managing Director
CFGI

David Levi
Executive Director, Global Business Controls, Corporate Controller’s Office
Bristol-Myers Squibb

Arnie Hanish
former Chief Accounting Officer, Eli Lilly & Co;
current Biotech Board Member

WORKSHOP E Methods and Hot Topics in Valuation

Andreas Chrysostomou
Managing Director
Duff & Phelps

5:40

Close of Workshops and Day Two

Join Us for a Cocktail Reception immediately following the close of workshops HOSTED BY: Deloitte

DAY THREE WEDNESDAY MARCH 22, 2017

7:30

Breakfast

8:30 ATTENDEES CHOOSE BETWEEN 3 TRACKS (I-III)

TRACK I BIG PHARMA

8:30

Track Chair’s Welcome and Insights

Jeff Ellis
Life Sciences Professional Practice Director
Deloitte & Touche LLP

8:45

OPENING PANEL Structuring Corporate Controllership/CAO Reporting in a Large Corporation

MODERATOR:

Mark A. Drozdowski
Partner, Life Sciences — National Audit Leader
KPMG

PANELISTS:

Matthew Busch
Director, Technical Accounting and External Reporting
Amgen

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

Jeffrey Draper
Senior Advisor on Corporate Financial Reporting
Eli Lilly & Co

Chris Tirona
Interim Global Corporate Controller
Indivior PLC

Jack Markey
Assistant Controller
Eisai, Inc.

James D’Arreca
Chief Accounting Officer
Allergan

9:30

BENCHMARKING SESSION Business vs. Asset in Practice —
Update on ASC 805 and Strategies to Best Distinguish Transactions

Jeff Ellis
Life Sciences Professional Practice Director
Deloitte & Touche LLP

Timothy Kocses
Director of Corporate Technical Accounting
Bristol-Myers Squibb

10:10

Life after Inversion — An In-Depth Look at Tax Strategies

Rob Schmidt
Principal
RSM US LLP

Aidan Byrne
Partner
RSM Ireland

TRACK II GENERICS AND BIOSIMILARS

8:30

Track Chair’s Welcome and Insights

Faith Glazier
Principal
Deloitte Consulting LLP

8:45

OPENING PANEL Navigating Change and Driving Growth within a Generics Business

MODERATOR:

Jeff Hendrey
Partner
PwC

PANELISTS:

Peter Licata
Chief Financial Officer
Rising Pharmaceuticals

Bryan Reasons
Chief Financial Officer
Impax Labs

Joel Morales
Senior Vice President Generics and Global Operations Finance
Par Pharmaceutical

9:30

Biosimilars Regulatory Matters and Policy Round-Up

Bruce Leicher
Senior Vice President and General Counsel
Momenta Pharmaceuticals

10:10

Revenue Management Strategies and Approaches for Successful GTN Processes

Speaker TBA

TRACK III BIOTECH

8:30

Track Chair’s Welcome and Insights

Ralph Marcello
US Biopharmaceutical Leader and Principal
Deloitte Consulting LLP

8:45

OPENING PANEL Scaling from a Growth Company to the Public Market — Stories and Lessons Learned

MODERATOR:

Graham Poles
Partner
PwC

PANELISTS:

Chad Cohen
Chief Financial Officer
Adaptive Biotechnologies

Matthew Gline
Senior Vice President, Finance and Business Operations
Roivant Sciences, Inc.

Michael Mason
Vice President of Finance and Treasurer
Alnylam Pharmaceuticals

9:30

Commercialization Strategies — Preparing for Product Approval

Bill Roberts
Partner
Ernst & Young LLP

Richard Capasso
Executive Director, Americas Financial Accounting Advisory Services
Ernst & Young LLP

Susan Garfield
Partner
Ernst & Young LLP

10:10

Building and Leading the Financial Organization within a High-Growth Biotech

Justin A. Renz, CPA, MST, MBA
Executive Vice President and Chief Financial Officer
Karyopharm

10:50

Close of Tracks; Networking and Refreshment Break

11:20 ATTENDEES CHOOSE BETWEEN 6 LEARNING LABS (1-6)

1 Optimizing Life Sciences Talent Acquisition and Business Financial Outcomes

Harry Griendling
Founder and CEO
DoubleStar, Inc.

2 Assessing Health Care Reform and ACA Policy Changes

Andrew B. Bressler, CFA
Managing Director, Global Research
Bank of America Merrill Lynch

3 Navigating Divestitures/Carve-Outs and Preparing Financial Statements

Subin Baral
Senior Manager, Transaction Advisory Services
Ernst & Young LLP

Brian Halligan
Partner
Ernst & Young LLP

Nancy Stempin
Executive Director
Ernst & Young LLP

Vineeta Dinesh
Director, Acquisition & Divestiture
Johnson & Johnson

James D’Arreca
Chief Accounting Officer
Allergan

4 Managing GTN for New Product Launch — Inception & Subsequent Quarters

Murray Kay
former Commercial Controller of Specialty Care
AbbVie Products, LLC

5 Implementing SOX Controls for Non-GAAP Measures

Steve Curry
Partner
Deloitte & Touche LLP

Joseph Sutter
Manager
Deloitte & Touche LLP

6 Establishing FP&A Frameworks for Success

George Carey
Executive Director
Ernst & Young LLP

Troy Norris
Executive Director
Ernst & Young LLP

Chris Reinholz
Senior Manager
Ernst & Young LLP

Lisa Banker
Northeast Life Sciences Transactions Market Leader
Ernst & Young LLP

12:20

Close of Learning Labs; Networking Luncheon

1:20

Revenue Recognition — Implementation and Benchmarking Course

Pamela Yanakopulos
Partner, Capital Markets and Accounting Advisory Services
PwC

Jillian Zandonella
Assurance Manager
PwC

3:20

Close of Congress

Agenda

Want more agenda details? Download the brochure.

Thank You For attending the Life Sciences
Accounting & Reporting Congress


We know you will continue to
MAINTAIN, NAVIGATE and ADAPT
all year long.

Wait until you see what's planned for 2018...

–The CBI Team

Want more agenda details? Download the brochure.

DAY ONE MONDAY MARCH 20, 2017

12:30

Congress Registration

1:30 ATTENDEES CHOOSE BETWEEN 3 SUMMITS (I-III)

I PHARMA/BIOTECH GROUP ROUNDTABLE (PART I)

Participate in a hot topic exchange and industry-only roundtable, as accounting leaders from pharmaceutical and biotech companies delve into pressing matters, emerging accounting guidance issues, shared challenges and areas of disparity in practice.

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

II PHARMA ACCOUNTING PRACTICUM — A NEXT LEVEL BOOT CAMP FOR CORPORATE PREPARERS

Rev up your understanding of industryspecific nuances and reinforce your control of technical accounting issues with high impact to pharmaceutical and biotech companies. This long-standing boot camp takes education to the next level as attendees are surveyed in advance and live during the event to illustrate disparities in practice and to hone in on top learning objectives.

Mike Lombardo
Partner
Deloitte

Brian Jobe
Partner
Deloitte

Bruce Rucks
Partner
Deloitte

III GROWTH PATH — CHALLENGES AND OPPORTUNITIES FOR ACHIEVING ACCELERATED GROWTH

Discover how leading life science companies achieve and manage accelerated growth, and learn the key considerations and strategic ‘watch-outs’ for various maturity stages in the business lifecycle. Hear challenges and opportunities to guide your business and to map the path towards continued accelerating growth.

Winna Brown
Partner
Ernst & Young LLP

Lily Yang
Vice President of Finance and Accounting
Medivation

Anthony Sgammato
Partner
Ernst & Young LLP

Chip Baird
Chief Financial Officer
Amicus Therapeutics

Suketu “Suky” Upadhyay
Senior Vice President of Global Finance Operations
Bristol-Myers Squibb

3:00

Networking and Refreshment Break

3:30 ATTENDEES CHOOSE BETWEEN 3 SUMMITS (IV-VI)

IV PHARMA/BIOTECH GROUP ROUNDTABLE (PART II)

Continue the conversation with your industry peers, as key topics are discussed. This industry-only roundtable solicits top learning objectives from registered participants in advance, as the discussions are ultimately guided by these top-of-mind matters.

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

V GTN ESTIMATES AND ACCRUALS — MASTER CLASS

The materiality around GTN has magnified in recent years. For companies at all stages of commercial revenue and at various junctures in the life sciences product lifecycle, it is critical that the focus sharpen around GTN process, estimates and controls. This session parlays substantial GTN expertise into a Master Class for life science companies.

Mike Makovec
Audit Senior Manager
Deloitte & Touche LLP

Brad Schulte
Senior Manager
Deloitte & Touche LLP

Walt Worsham
Senior Manager
Deloitte & Touche LLP

Larry Breen
Director of Financial Planning and Analysis/Revenue Analytics
Sunovion

David Levi
Executive Director, Global Business Controls, Corporate Controller’s Office
Bristol-Myers Squibb

Jeffrey R. Miller
Director, Revenue Accounting and Contract Administration
Impax Labs

VI WOMEN’S LEADERSHIP SUMMIT Spotlights power players in the Finance function and shares stories on career paths, mentorship and leadership

An all-new, important Summit showcasing women in leadership within the finance and life sciences community. Hear compelling stories of personal career success, reflect on professional development paths, discover flashpoint moments, and ways to inspire and elevate the finance team. Attendees discover meaningful mentorships and insights into optimal job placement and professional pathways.

MODERATOR:

Karen Young
U.S. Pharmaceutical and Life Sciences Assurance Leader
PwC

PANELISTS:

Joyce LaViscount
Chief Financial Officer
Helius Medical

Kristine Ball
Former Chief Financial Officer
Relypsa

Sharon Greenlees
Vice President of Investor Relations
AbbVie

Ann Powell Judge
Chief Human Resources Officer
Bristol-Myers Squibb

Maria Teresa “Tessa” Hilado
Chief Financial Officer
Allergan (Invited)

5:00

Close of Day One

JOIN US FOR THE OPENING NIGHT WELCOME RECEPTION immediately following the final session on day one HOSTED BY: Ernst & YoungSiegfried Group

DAY TWO TUESDAY, MARCH 21, 2017

6:00

“Rocky Run”   Hosted by: PwC

Join PwC and industry colleagues in a morning “Rocky Run”. Participants depart the hotel at 6am and run just under 3 miles to the Philadelphia Art Museum, ascending the famous Rocky Steps and taking a photo with Rocky’s statue. Do not miss this traditional Philadelphia right of passage! Return transportation provided.

7:00

Breakfast and Registration

8:00

CBI Welcome

8:20

Co-Chairs’ Welcome and Opening Remarks

Cathy Engelbert
CEO
Deloitte LLP

Chris Cooper
Partner, National Audit Life Sciences and Health Care Leader
Deloitte & Touche LLP

9:00

KEYNOTE PANEL Product Pricing, Payer Pressure and Patient Access —
Transcending the Higher Bar in Today’s Value-Based Life Science Landscape

MODERATOR:

Karen Young
U.S. Pharmaceutical and Life Sciences Assurance Leader
PwC

PANELISTS:

Ira Klein
Senior Director of Healthcare Quality Strategy, Strategic Customer Group
Janssen Pharmaceuticals;
former National Medical Director for Clinical Thought Leadership
in the Office of the Chief Medical Officer, Aetna

Steve Miller
Chief Medical Officer
Express Scripts

Michelle Drozd
Deputy Vice President of Policy and Research
Pharmaceutical Research and Manufacturers of America (PhRMA)

Rebecca Shanahan
Chief Executive Officer
Avella Specialty Pharmacy

Matt Eyles
Executive Vice President, Policy & Regulatory Affairs
America’s Health Insurance Plans (AHIP)

10:00

Networking and Refreshment Break

10:30

LUMINARY SEGMENT Progressive Pharma —
Building Digital into the DNA of the Industry

This highly-acclaimed Luminary Segment showcases industry changemakers and illustrates innovation moonshots in the areas of R&D, technology, health outcomes and commercial finance. Discover how pharmaceutical companies are disrupting the course of business, reshaping the state of play, and truly elevating the patient experience.

MODERATOR:

Tim Gordon
Global FAAS Life Sciences Leader
Ernst & Young LLP

I. Transforming Clinical Research and Fueling Outcomes-driven, Patient-centric Drug Discovery and Development

LUMINARY:

Greg Simon
Director
Biden Cancer Initiative at Biden Foundation

II. Revolutionizing the Patient Journey and Catalyzing Commercial Innovation with Technology

LUMINARY:

Iya Khalil
Co-Founder and Chief Commercial Officer
GNS Healthcare

III. Optimizing Business Activities and Finance Transformation to Hit New Heights in Efficiency

LUMINARY:

Carolee Clarke-Reid
Director, Global Tax Operation
Johnson & Johnson

12:30

Networking Luncheon

REGULATORY INSIGHTS

MODERATOR:

Christine Davine
Deputy Managing Partner
Deloitte & Touche LLP

1:30

SEC KEYNOTE ADDRESS Impact of New Administration on SEC Priorities and Agenda

Wesley Bricker
Chief Accountant
U.S. Securities & Exchange Commission

2:10

SEC Hot Topics in the Life Sciences Industry —
Comment Letter Review and Key Industry Matters

James Rosenberg
Senior Assistant Chief Accountant in the Office of Health Care and Insurance
U.S. Securities & Exchange Commission

2:50

FASB ADDRESS The Future of Global Standard Setting and Initiatives to Make Standards More Comparable

Russell Golden
Chairman
FASB

3:30

MARKET MATTERS Walk Down Wall Street and View the Most Impactful Deals and Breakthroughs Impacting the Life Science Sector

MODERATOR:

Colin Wittmer
New York Metro Deals & Transaction Services Leader
PwC

PANELISTS:

Kennen MacKay, PhD
Vice President, Biotechnology Research Analyst
Credit Suisse

Gerardo Ubaghs
Vice President (Life Sciences), Global Healthcare Investment Banking
Bank of America Merrill Lynch

4:10

Networking and Refreshment Break

4:40 ATTENDEES CHOOSE FROM FOUR WORKSHOPS (A,B,D,E)

WORKSHOP A Accounting Considerations for Licensing Arrangements

Dennis Howell
Partner
Deloitte & Touche LLP

Robert Owens
Assistant Controller
Bristol-Myers Squibb

WORKSHOP B Applying the New Lease Standard

Shanti Gupta
Senior Manager
Ernst & Young LLP

Kevin MacKay
Assistant Corporate Controller
Pfizer Inc

Robert (Rob) Auslander, CPA, CGMA, MBA
Vice President, Technical Accounting and Policies
Valeant Pharmaceuticals International

Joe Fitzgerald
Executive Director
Ernst & Young LLP

WORKSHOP D Optimizing Controls and Compliance

Jim Quinlan
Partner
CFGI

Angela Celia
Managing Director
CFGI

David Levi
Executive Director, Global Business Controls, Corporate Controller’s Office
Bristol-Myers Squibb

Arnie Hanish
former Chief Accounting Officer, Eli Lilly & Co;
current Biotech Board Member

WORKSHOP E Methods and Hot Topics in Valuation

Andreas Chrysostomou
Managing Director
Duff & Phelps

5:40

Close of Workshops and Day Two

Join Us for a Cocktail Reception immediately following the close of workshops HOSTED BY: Deloitte

DAY THREE WEDNESDAY MARCH 22, 2017

7:30

Breakfast

8:30 ATTENDEES CHOOSE BETWEEN 3 TRACKS (I-III)

TRACK I BIG PHARMA

8:30

Track Chair’s Welcome and Insights

Jeff Ellis
Life Sciences Professional Practice Director
Deloitte & Touche LLP

8:45

OPENING PANEL Structuring Corporate Controllership/CAO Reporting in a Large Corporation

MODERATOR:

Mark A. Drozdowski
Partner, Life Sciences — National Audit Leader
KPMG

PANELISTS:

Matthew Busch
Director, Technical Accounting and External Reporting
Amgen

Stephen Rivera
Worldwide Senior Director for Financial Compliance and Procedures
Johnson & Johnson

Jeffrey Draper
Senior Advisor on Corporate Financial Reporting
Eli Lilly & Co

Chris Tirona
Interim Global Corporate Controller
Indivior PLC

Jack Markey
Assistant Controller
Eisai, Inc.

James D’Arreca
Chief Accounting Officer
Allergan

9:30

BENCHMARKING SESSION Business vs. Asset in Practice —
Update on ASC 805 and Strategies to Best Distinguish Transactions

Jeff Ellis
Life Sciences Professional Practice Director
Deloitte & Touche LLP

Timothy Kocses
Director of Corporate Technical Accounting
Bristol-Myers Squibb

10:10

Life after Inversion — An In-Depth Look at Tax Strategies

Rob Schmidt
Principal
RSM US LLP

Aidan Byrne
Partner
RSM Ireland

TRACK II GENERICS AND BIOSIMILARS

8:30

Track Chair’s Welcome and Insights

Faith Glazier
Principal
Deloitte Consulting LLP

8:45

OPENING PANEL Navigating Change and Driving Growth within a Generics Business

MODERATOR:

Jeff Hendrey
Partner
PwC

PANELISTS:

Peter Licata
Chief Financial Officer
Rising Pharmaceuticals

Bryan Reasons
Chief Financial Officer
Impax Labs

Joel Morales
Senior Vice President Generics and Global Operations Finance
Par Pharmaceutical

9:30

Biosimilars Regulatory Matters and Policy Round-Up

Bruce Leicher
Senior Vice President and General Counsel
Momenta Pharmaceuticals

10:10

Revenue Management Strategies and Approaches for Successful GTN Processes

Speaker TBA

TRACK III BIOTECH

8:30

Track Chair’s Welcome and Insights

Ralph Marcello
US Biopharmaceutical Leader and Principal
Deloitte Consulting LLP

8:45

OPENING PANEL Scaling from a Growth Company to the Public Market — Stories and Lessons Learned

MODERATOR:

Graham Poles
Partner
PwC

PANELISTS:

Chad Cohen
Chief Financial Officer
Adaptive Biotechnologies

Matthew Gline
Senior Vice President, Finance and Business Operations
Roivant Sciences, Inc.

Michael Mason
Vice President of Finance and Treasurer
Alnylam Pharmaceuticals

9:30

Commercialization Strategies — Preparing for Product Approval

Bill Roberts
Partner
Ernst & Young LLP

Richard Capasso
Executive Director, Americas Financial Accounting Advisory Services
Ernst & Young LLP

Susan Garfield
Partner
Ernst & Young LLP

10:10

Building and Leading the Financial Organization within a High-Growth Biotech

Justin A. Renz, CPA, MST, MBA
Executive Vice President and Chief Financial Officer
Karyopharm

10:50

Close of Tracks; Networking and Refreshment Break

11:20 ATTENDEES CHOOSE BETWEEN 6 LEARNING LABS (1-6)

1 Optimizing Life Sciences Talent Acquisition and Business Financial Outcomes

Harry Griendling
Founder and CEO
DoubleStar, Inc.

2 Assessing Health Care Reform and ACA Policy Changes

Andrew B. Bressler, CFA
Managing Director, Global Research
Bank of America Merrill Lynch

3 Navigating Divestitures/Carve-Outs and Preparing Financial Statements

Subin Baral
Senior Manager, Transaction Advisory Services
Ernst & Young LLP

Brian Halligan
Partner
Ernst & Young LLP

Nancy Stempin
Executive Director
Ernst & Young LLP

Vineeta Dinesh
Director, Acquisition & Divestiture
Johnson & Johnson

James D’Arreca
Chief Accounting Officer
Allergan

4 Managing GTN for New Product Launch — Inception & Subsequent Quarters

Murray Kay
former Commercial Controller of Specialty Care
AbbVie Products, LLC

5 Implementing SOX Controls for Non-GAAP Measures

Steve Curry
Partner
Deloitte & Touche LLP

Joseph Sutter
Manager
Deloitte & Touche LLP

6 Establishing FP&A Frameworks for Success

George Carey
Executive Director
Ernst & Young LLP

Troy Norris
Executive Director
Ernst & Young LLP

Chris Reinholz
Senior Manager
Ernst & Young LLP

Lisa Banker
Northeast Life Sciences Transactions Market Leader
Ernst & Young LLP

12:20

Close of Learning Labs; Networking Luncheon

1:20

Revenue Recognition — Implementation and Benchmarking Course

Pamela Yanakopulos
Partner, Capital Markets and Accounting Advisory Services
PwC

Jillian Zandonella
Assurance Manager
PwC

3:20

Close of Congress